ATHENS, Georgia, Aug. 19 GA-ArunA-Licensing
ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a leader
in human embryonic stem cell derived products, announced today that it has
entered into an exclusive worldwide technology licensing agreement with the
University of Georgia Research Foundation that will enable the company to
commercialize human mesenchymal cells developed at the University of Georgia.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO )
Under the terms of the agreement, ArunA has acquired an exclusive
worldwide license to develop and commercialize human mesenchymal cells
(hMSC(TM)) derived from human embryonic stem cells, a product never before
available. ArunA will offer the academic and industrial research communities
access to a highly uniform population of human mesenchymal cells grown as
adherent monolayer cultures in multiple turn-key kit formats. The hMSC kits
will provide a physiologically relevant and genetically stable source of
research material for use in a broad range of life science research
applications such as: developmental pathway studies, disease modeling, in
vitro toxicology, compound screening and humanized animal models.
"ArunA's proprietary adherent monolayer culture technology creates
millions of highly uniform cells. These unique cells provide researchers with
new enabling tools that can have a measurable impact on the advancement of
drug discovery," says ArunA Biomedical President and Chief Executive Officer,
William Sharp. "We are targeting an early first quarter 2009 launch of
ArunA's first hMSC kit."
According to Robert Nerem, the Parker H. Petit Distinguished Chair for
Engineering in Medicine at the Georgia Institute of Technology, "One of the
most important uses of human embryonic stem cells will be in the generation of
uniform populations of adult stem cells and progenitor cells. It is thus
exciting that ArunA Biomedical will be able to provide uniform cell
populations of human mesenchymal cells in kit form. This not only will be of
value to bench scientists, but also in advancement toward clinical therapies."
About ArunA Biomedical
Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held
biotechnology corporation dedicated to the discovery, manufacturing and
commercialization of emerging new technologies in human stem cell research for
use in drug discovery and basic research. ArunA is the first company to
commercialize products derived from human embryonic stem cells and sees its
proprietary technology as a catalyst leading to the discovery of novel
therapeutic compounds, tests for neurotoxicity and breakthroughs in
understanding human development and diseases.
www.arunabiomedical.com
SOURCE ArunA Biomedical, Inc.
